Clinical Trial Update: Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial updates the efficacy and safety of oral CEP-701 (lestaurtinib) in patients with advanced multiple myeloma, with the study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CEP-701 (lestaurtinib)

Snippet

Sponsor: Cephalon | Conditions: Myeloma | Phase 2 | Status: TERMINATED